Anti-infective antibodies: a novel tool to prevent and treat nosocomial diseases

References

• Almond JW. Vaccine renaissance. Nat. Rev. Microbiol.5, 478–481 (2007).
   PubMed Web of Science ®Google Scholar
• Buchwald UK, Pirofski L. Immune therapy for infectious diseases at the dawn of the 21st century: the past, present and future role of antibody therapy, therapeutic vaccination and biological response modifiers. Curr. Pharm. Des.9, 945–968 (2003).
   PubMed Web of Science ®Google Scholar
• Behring EA, Kisato, S. Ueber das zustandekommen der diphterie-immunität und der tetanus-immunität bei thieren. Curr. Pharm. Des.49, 1113–1114 (1890).
   Google Scholar
• Casadevall A, Dadachova E, Pirofski LA. Passive antibody therapy for infectious diseases. Nat. Rev. Microbiol.2(9), 695–703 (2004).
   PubMed Web of Science ®Google Scholar
• Impact-RSV study group. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn. Pediatrics102(5), 1211–1216 (1998).
   PubMed Web of Science ®Google Scholar
• Moellering RC Jr, Graybill JR, McGowan JE Jr, Corey L. Antimicrobial resistance prevention initiative – an update: proceedings of an expert panel on resistance. Am. J. Med.120(7), S4–S25 (2007).
   PubMed Web of Science ®Google Scholar
• Wenzel RP. Health care-associated infections: major issues in the early years of the 21st century. Clin. Infect. Dis.15(45 Suppl. 1), S85–S88 (2007).
   Google Scholar
• Schmidt FR. The challenge of multidrug resistance: actual strategies in the development of novel antibacterials. Appl. Microbiol. Biotechnol. 63(4), 335–343 (2004).
   PubMed Web of Science ®Google Scholar
• Patti JM. Immunotherapeutics for nosocomial infections. Expert Opin. Investig. Drugs13(6), 673–679 (2004).
   PubMed Web of Science ®Google Scholar
• Murphy D, Whiting J, Hollenbeak CS. An APIC briefing (Association for Professionals in Infection Control and Epidemiology). Dispelling the myths: the true cost of healthcare-associated infections. February (2007).
   Google Scholar
• Tenover FC. Mechanisms of antimicrobial resistance in bacteria. Am. J. Med.119(6 Suppl 1), S3–S10 (2006).
   PubMed Web of Science ®Google Scholar
• Lipsitch M, Samore MH. Antimicrobial use and antimicrobial resistance: a population perspective. Emerg. Infect. Dis.8(4), 347–354 (2002).
   PubMed Web of Science ®Google Scholar
• Richardson MD. Changing patterns and trends in systemic fungal infections. J. Antimicrob. Chemother.56(Suppl. 1), i5–i11 (2005).
   PubMed Web of Science ®Google Scholar
• Amyes SG. Enterococci and streptococci. Int. J. Antimicrob. Agents29(Suppl. 3), S43–S52 (2007).
   PubMed Web of Science ®Google Scholar
• Nordmann P, Naas T, Fortineau N, Poirel L. Superbugs in the coming new decade; multidrug resistance and prospects for treatment of Staphylococcus aureus, Enterococcus spp. and Pseudomonas aeruginosa in 2010. Curr. Opin. Microbiol.10(5), 436–440 (2007).
   PubMed Web of Science ®Google Scholar
• Rice LB. Antimicrobial resistance in Gram-positive bacteria. Am. J. Med.119, S11–S19 (2006).
   PubMedGoogle Scholar
• Castaldo ET, Yang EY. Severe sepsis attributable to community-associated methicillin-resistant Staphylococcus aureus: an emerging fatal problem. Am. Surg.73(7), 684–687 (2007).
   PubMedGoogle Scholar
• Kollef MH, Micek ST. Methicillin-resistant Staphylococcus aureus: a new community-acquired pathogen? Curr. Opin. Infect. Dis.19, 161–168 (2006).
   PubMed Web of Science ®Google Scholar
• Nitsche-Schmitz DP, Rohde M, Chhatwal GS. Invasion mechanisms of Gram-positive pathogenic cocci. J. Thromb. Haemost.98, 488–496 (2007).
   Google Scholar
• Fabrizio K, Groner A, Boes M, Pirofski L. A human monoclonal immunoglobulin M reduces bacteremia and inflammation in a mouse model of systemic pneumococcal infection. Clin. Vaccine Immunol.14(4), 382–390 (2007).
   PubMedGoogle Scholar
• Casadevall A, Pirofski L. Antibody mediated regulation of cellular immunity and the inflammatory response. Trends Immunol.24, 474–478 (2003).
   PubMed Web of Science ®Google Scholar
• Casadevall A, Pirofski L. New concepts in antibody-mediated immunity. Infect. Immun.72, 6191–6196 (2004).
   PubMed Web of Science ®Google Scholar
• Holzheimer RG. Antibiotic induced endotoxin release and clinical sepsis: a review. J. Chemother.13 (1), 159–172 (2001).
   PubMed Web of Science ®Google Scholar
• Rappuoli R, Covacci A. Reverse vaccinology and genomics. Science 302(5645),602 (2003) .
   Google Scholar
• Meinke A, Henics T, Hanner M, Minh DB, Nagy E. Antigenome technology: a novel approach for the selection of bacterial vaccine candidate antigens. Vaccine23(17–18), 2035–2041 (2005).
   PubMed Web of Science ®Google Scholar
• Meinke A, Henics T, Nagy E. Bacterial genomes pave the way to novel vaccines. Curr. Opin. Microbiol.7(3), 314–320 (2004).
   PubMed Web of Science ®Google Scholar
• Giefing C, Nagy E, von Gabain A. The antigenome: from protein subunit vaccines to antibody treatments of bacterial infections.In: Pharmaceutical Biotechnology. Guzman CA, Feuerstein G (Eds). Landes Bioscience, TX, USA (2008) (In press).
   Google Scholar
• Albrecht MT, Li H, Williamson ED et al. Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax. Infect. Immun.75(11), 5425–5433 (2007).
   PubMed Web of Science ®Google Scholar
• Coughlin M, Lou G, Martinez O et al. Generation and characterization of human monoclonal neutralizing antibodies with distinct binding and sequence features against SARS coronavirus using XenoMouse. Virology.361, 93–102 (2007).
   PubMed Web of Science ®Google Scholar
• Nowakowski A, Wang C, Powers DB et al. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc. Natl Acad. Sci. USA99, 11346–11350 (2002).
   PubMed Web of Science ®Google Scholar
• Wiberg FC, Rasmussen SK, Frandsen TP et al. Production of target-specific recombinant human polyclonal antibodies in mammalian cells. Biotechnol. Bioeng.94, 396–405 (2006).
   PubMed Web of Science ®Google Scholar
• Logtenberg T. Antibody cocktails: next-generation biopharmaceuticals with improved potency. Trends Biotechnol.25, 390–394 (2007).
   PubMed Web of Science ®Google Scholar
• Pendley C, Schantz A, Wagner C. Immunogenicity of therapeutic monoclonal antibodies. Curr. Opin. Mol. Ther.5(2), 172–179 (2003).
   PubMedGoogle Scholar
• Klee GG. Human anti-mouse antibodies. Arch. Pathol. Lab. Med.124(6), 921–923 (2000).
   PubMed Web of Science ®Google Scholar
• Jefferis R. Antibody therapeutics: isotype and glycoform selection. Expert Opin. Biol. Ther.7, 1401–1413 (2007).
   PubMed Web of Science ®Google Scholar
• Ferrara C, Brunker P, Suter T et al. Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous β1, 4N-acetylglucosaminyltransferase III and Golgi α-mannosidase II. Biotechnol.Bioeng.93, 851–861 (2006).
   PubMed Web of Science ®Google Scholar
• Burnie JP, Carter TL, Hodgetts SJ, Matthews RC. Fungal heat-shock proteins in human disease. FEMS Microbiol. Rev.30(1), 53–88 (2006).
   PubMed Web of Science ®Google Scholar
• Matthews RC, Burnie JP. Recombinant antibodies: a natural partner in combinatorial antifungal therapy. Vaccine22(7), 865–871 (2004).
   PubMed Web of Science ®Google Scholar
• Rigg GP, Matthews RC, Donohoe MS et al. Aurograb shows broad spectrum synergy with vancomycin against MRSA and VISA (vancomycin-intermediate) strains of Staphylococcus aureus. Presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, USA, (2002) (Abstract E-1645).
   Google Scholar
• Carter PJ. Potent antibody therapeutics by design.Nat Rev Immunol6(5), 343–357 (2006).
   PubMed Web of Science ®Google Scholar
• Kim SJ, Park Y, Hong HJ. Antibody engineering for the development of therapeutic antibodies. Mol. Cell.20(1), 17–29 (2005).
   Google Scholar
• Hoogenboom HR. Overview of antibody phage-display technology and its applications. Methods Mol. Biol.178, 1–37 (2002).
   PubMedGoogle Scholar
• Meijer PJ, Andersen PS, Haahr Hansen M et al. Isolation of human antibody repertoires with preservation of the natural heavy and light chain pairing. J. Mol. Biol.358, 764–772 (2006).
   PubMed Web of Science ®Google Scholar
• Lanzavecchia A, Bernasconi N, Traggiai E, Ruprecht CR, Corti D, Sallusto F. Understanding and making use of human memory B cells. Immunol. Rev.211, 303–309 (2006).
   PubMed Web of Science ®Google Scholar
• Lonberg N. Human antibodies from transgenic animals. Nat. Biotechnol.23(9), 1117–1125 (2005).
   PubMed Web of Science ®Google Scholar
• Pachl J, Svoboda P, Jacobs F et al. A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin. Infect. Dis.42, 1404–1413 (2006).
   PubMed Web of Science ®Google Scholar
• Matthews RC, Rigg G, Hodgetts S et al. Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90. Antimicrob. Agents Chemother.47(7), 2208–2216 (2003).
   PubMed Web of Science ®Google Scholar
• Burnie JP, Matthews RC, Carter T et al. Identification of an immunodominant ABC transporter in methicillin-resistant Staphylococcus aureus infections. Infect. Immun.68(6), 3200–3209 (2000).
   PubMed Web of Science ®Google Scholar
• Matthews RC, Burnie JP, Tabaqchali S. Isolation of immunodominant antigens from sera of patients with systemic candidiasis and characterization of serological response to Candida albicans. J. Clin. Microbiol.25, 230–237 (1987).
   PubMed Web of Science ®Google Scholar
• Vernachio JH, Bayer AS, Ames B et al. Human immunoglobulin G recognizing fibrinogen-binding surface proteins is protective against both Staphylococcus aureus and Staphylococcus epidermidis infections in vivo. Antimicrob. Agents Chemother.50(2), 511–518 (2006).
   PubMed Web of Science ®Google Scholar
• Kuklin NA, Clark DJ, Secore S et al. A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S. aureus sepsis model. Infect. Immun.74(4), 2215–2223 (2006).
   PubMed Web of Science ®Google Scholar
• Etz H, Minh DB, Henics T et al. Identification of in vivo expressed vaccine. candidate antigens from Staphylococcus aureus.Proc. Natl Acad. Sci. USA99(10), 6573–6578 (2002).
   PubMed Web of Science ®Google Scholar
• Dryla A, Prustomersky S, Gelbmann D et al. Comparison of antibody repertoires against Staphylococcus aureus in healthy individuals and in acutely infected patients. Clin. Diagn. Lab. Immunol.12(3), 387–398 (2005).
   PubMedGoogle Scholar
• Baker M. Anti-infective antibodies: finding the path forward. Nat. Biotechnol.24, 1491–1493 (2006).
   PubMed Web of Science ®Google Scholar